Semarion is a University of Cambridge spin-out from the Cavendish Laboratory developing next-generation tools to accelerate cell-based drug discovery. Its proprietary SemaCyte® platform turns adherent cells into barcoded, assay-ready, automation-friendly reagents, enabling researchers to multiplex cell models, increase throughput, and generate richer datasets using existing tools and workflows. Semarion is combining materials engineering, microfabrication, and cell biology to remove bottlenecks in adherent cell assays and unlock 10x gains in data generation.
Semarion: Venture Capital Funding History
Semarion
Semarion
- Life Sciences
- Cambridge, United Kingdom
- £2.9m
- semarion.com
- Update Information
More venture news
- 23 Sept 2026

Basecamp ResearchBasecamp Research unlocks £105m Series C led by S32 to design medicines with frontier AI models
Series CLife Sciences - 18 Sept 2026

Big Picture BioBig Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences - 16 Sept 2026

Eterna RegenerativesEterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair
SeedLife Sciences
